Company intelligence / Profile preview

Highline Bio

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Highline Bio is a New York-based biotechnology company focused on the development of novel precision medicines for patients with high unmet medical needs. Incubated and backed by Versant Ventures, the company leverages a proprietary platform to identify and validate therapeutic targets in areas such as oncology and immunology. Highline Bio operates at the intersection of data science and drug discovery to accelerate the delivery of targeted therapies. The company is currently in the pre-clinical stage, advancing a pipeline of small molecule and biologic candidates.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Versant Ventures

Beyond the preview

Go deeper on Highline Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Highline Bio.

Explore the full profile